

Synthesis and biological evaluation of [1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a] indoles: one-pot reaction under microwave irradiation

Abhilasha Dubba  and Koppula Shiva Kumar *

Department of Chemistry, GITAM deemed to be University, Hyderabad campus, Rudraram,
Sangareddy, Hyderabad, 502329, Telangana, India

(Received July 10, 2023; Revised August 21, 2023; Accepted August 27, 2023)

Abstract: The synthesis and structural determination of several new fused [1,2,3]triazolo-[4',5':3,4]pyrrolo-[1,2-a]indole derivatives (**4a-4p**) utilising ¹HNMR, ¹³CNMR, and mass spectrum analysis were discussed. The *in vitro* antibacterial activity of the compounds (**4a-4p**) against three gramme positive bacterial strains such as *B.subtilis*, *S.aureus*, and *S.epidermidis* revealed that the compounds **4h**, **4j**, and **4k** demonstrated greater activity than the remaining compounds. Compounds **4d**, **4i**, and **4l** had comparable activity to the standard. The antioxidant activity screening findings show that compounds **4c**, **4d**, and **4j** have higher activity than conventional Trolox. Compounds **4b**, **4h**, **4k**, and **4l** have high activity, whereas the remaining compounds have moderate to low activity.

Keywords: Indole; fused 1,2,3-triazole; MWI; antibacterial activity; antioxidant activity. ©2023 ACG Publication. All right reserved.

1. Introduction

The fact that pathogenic bacteria are growing more resistant to antibiotics is a major source of concern for public health organisations around the world. Bacteria are single-celled bacteria that are normally harmless to humans and, in some cases, beneficial.¹ Some bacteria, on the other hand, are hazardous and can cause significant diseases.² As a result, it is critical for public health to develop treatments for microbial infections caused by microbiologically resistant organisms.³ As a result, there is a critical need for new, stronger antimicrobial medicines with broad inhibitory action, efficacy, and low toxicity. So, a solid method for developing novel antibacterial agents with new modes of action and structural alterations is required to make them more effective and selective for their targets.

Indole derivatives are a promising heterocyclic group with active sites that have the potential to treat a wide range of ailments.^{4,5} Many publications have been written regarding indole fragments and their products, which have the potential to fight cancer⁶⁻⁸ and it will kill bacteria.⁹ Over the last few years, fused 1,2,3-triazoles and their hybrids have been the most preferred "lead compounds" in drug discovery. This is due to the fact that they are simple to manufacture and have intriguing pharmacological properties.¹⁰⁻¹³ Many antibacterial medicines based on fused 1,2,3-triazole derivatives have also been developed.¹⁴

As a follow-up to our research on new heterocyclic compounds,¹⁵⁻¹⁹ and in light of what has been stated above, we have decided to continue looking into indole-based 1,2,3-triazoles derivatives,²⁰

* Corresponding author: E-Mail: shivak.koppula78@gmail.com

Synthesis and biological activity of fused 1,2,3-triazoles

with the goal of discovering new compounds with antibacterial and antioxidant properties that could be used to develop new drugs. As illustrated in Figure 1, we created combined [1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-*a*]indole scaffolds by merging the functionalities of the indole group and the 1,2,3-triazole. Every chemical developed was tested to see if it might kill bacteria or fight free radicals.




Figure 1: Propose plan for new fused [1,2,3] triazolo[4',5':3,4] pyrrolo[1,2-*a*]indole hybrids.

2. Experimental

2.1. Chemical Material and Apparatus

All solvents and starting materials were purchased commercially and used without additional purification. The NMR spectra for ^1H and ^{13}C were acquired using a Bruker (400 MHz for ^1H and 100 MHz for ^{13}C). Mass spectra were collected using a Jeol JMC-300 spectrometer (ESI, 70 eV). The Carlo Erba 106 and PerkinElmer model 240 analyzers were used to analyse the elements. A Cintex equipment was used to determine uncorrected melting points. TLC was carried out on Merck silica gel 60 F254 precoated plates (0.25 mm), while column chromatography was carried out on silica gel (100-200 mesh). TLC with EtOAc-hexane as an eluent was employed to monitor the progress of the reactions as well as the purity of the compounds.

2.2. Synthesis of 2-iodo-1-(prop-2-yn-1-yl)-1H-indole (**2**)

For 6 hours, a combination of 2-iodo-1H-indole (**1**) (5g, 0.02 mol), K_2CO_3 (0.06 mol), and propargyl bromide (0.026 mol) in DMF (60 mL) was agitated at 60 °C. After the reaction was completed, the mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The mixed organic layer was washed with brine (2x50 mL), dried with anhydrous Na_2SO_4 , and then concentrated under vacuum to yield compound (**2**) (72%). ^1H NMR (400MHz, DMSO-d_6 ; in ppm): δ 7.70 (d, $J = 8.0$ Hz, 1H), 7.50 (d, $J = 8.0$ Hz, 1H), 7.35 - 7.30 (m, 1H), 7.20 (s, 1H), 7.10 - 7.05 (m, 1H), 3.75 (d, $J = 4.0$ Hz, 2H, NCH_2), 2.21 (t, $J = 4.0$ Hz, 1H, alkyne-H); ESI-MS(m/z): 200 [$\text{M}+\text{H}$] $^+$.

2.3.3. Synthesis of 1-(aryl)-1,4-dihydro[1,2,3]triazolo-[4',5':3,4]pyrrolo-[1,2-*a*]indole (**4a-4p**):

CuI (10 mol%) was added to a solution of 2-iodo-1-(prop-2-yn-1-yl)-1H-indole (**2**) (1.0 mmol), aryl azide (1.2 mmol), and $t\text{BuOK}$ (3.0 mmol) in a microwave reactor vessel (10 mL). The mixture was heated at 100 °C for 30-40 minutes. TLC was used to track the course of the reaction. The reaction mixture was carefully emptied into ice-cold water (10 mL) and the product was extracted with ethyl acetate (2x15 mL) after the container was allowed to cool at room temperature. The organic layers were washed in brine and dried over anhydrous Na_2SO_4 . Following filtration, the solvent was evaporated

under vacuum, and the crude product produced was refined using column chromatography (hexane/ethyl acetate gradient) to yield the pure needed product.

1-phenyl-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4a): Color: White crystalline solid (74% yield); M.P: 122-124 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.71 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.60 - 7.56 (m, 2H, Ar-H), 7.52 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.43 - 7.39 (m, 3H, Ar-H), 7.33 - 7.28 (m, 1H, Ar-H), 7.21 (s, 1H, Ar-H), 7.10 - 7.05 (m, 1H, Ar-H), 5.23 (s, 2H, CH₂); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.24, 139.54, 136.50, 135.33, 129.67(2C), 128.40, 127.34, 124.80, 124.23(2C), 123.49, 122.32, 121.35, 110.76, 107.79, 42.23; ESI-MS(*m/z*): 273 [M+H]. Anal.Cal for C₁₇H₁₂N₄; C, 74.98; H, 4.44; N, 20.58; found C, 74.94; H, 4.46; N, 20.60.

1-(4-methoxyphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4b): Color: White crystalline solid (71% yield); M.P: 130-132 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.78 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.70 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.54 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.35 - 7.31 (m, 1H, Ar-H), 7.19 (s, 1H, Ar-H), 7.10 - 7.06 (m, 1H, Ar-H), 6.99 (d, *J* = 8.0 Hz, 2H, Ar-H), 5.25 (s, 2H, CH₂), 3.84 (s, 3H, -OCH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.66, 159.79, 139.60, 135.09, 131.39, 127.85, 126.37(2C), 124.33, 123.42, 122.52, 121.21, 114.88(2C), 110.45, 108.39, 56.21, 42.36; ESI-MS(*m/z*): 303 [M+H]. Anal.Cal for C₁₈H₁₄N₄O; C, 71.51; H, 4.67; N, 18.53; found C, 71.54; H, 4.65; N, 18.51.

1-(3,5-dimethoxyphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4c): Color: Pale yellow solid (68% yield), M.P: 156-158 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.72 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.60 (s, 2H, Ar-H), 7.52 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.30 - 7.26 (m, 1H, Ar-H), 7.22 (s, 1H, Ar-H), 7.11 - 7.06 (m, 1H, Ar-H), 7.02 (s, 1H, Ar-H), 5.23 (s, 2H, CH₂), 3.83 (s, 6H, 2-OCH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.45, 159.24(2C), 139.67, 138.37, 135.35, 127.51, 124.26, 123.35, 122.70, 121.51, 110.72, 107.21, 104.92(2C), 102.96, 56.18(2C), 42.28; ESI-MS(*m/z*): 333 [M+H]. Anal.Cal for C₁₉H₁₆N₄O₂; C, 68.66; H, 4.85; N, 16.86; found C, 68.69; H, 4.83; N, 16.84.

1-(4-chloro-3,5-dimethoxyphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4d): Color: Yellow crystalline solid (78 % yield), M.P: 164-166 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.73 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.51 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.36 - 7.32 (m, 1H, Ar-H), 7.21 (s, 1H, Ar-H), 7.15 (s, 2H, Ar-H), 7.09 - 7.05 (m, 1H, Ar-H), 5.24 (s, 2H, CH₂), 3.85 (s, 6H, 2-OCH₃); ¹³C-NMR (100 MHz, DMSO-d₆) 161.53, 156.57(2C), 139.30, 138.09, 135.25, 127.30, 124.19, 123.29, 122.56, 121.08, 118.42, 110.54, 107.72, 104.70(2C), 56.66(2C), 42.27; ESI-MS(*m/z*): 367 [M+H]. Anal.Cal for C₁₉H₁₅ClN₄O₂; C, 62.21; H, 4.12; N, 15.27; found C, 62.23; H, 4.14; N, 15.23.

1-(p-tolyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4e): Color: White solid (70 % yield); M.P: 127-129 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.72 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.66 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.51 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.42 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.35 - 7.30 (m, 1H, Ar-H), 7.22 (s, 1H, Ar-H), 7.10 - 7.06 (m, 1H, Ar-H), 5.25 (s, 2H, CH₂), 2.31 (s, 3H, -CH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.61, 139.38, 138.49, 136.87, 135.18, 130.05 (2C), 127.63, 125.77(2C), 124.08, 123.03, 122.08, 121.09, 110.61, 107.48, 42.37, 21.36; ESI-MS(*m/z*): 287 [M+H]. Anal.Cal for C₁₈H₁₄N₄; C, 75.50; H, 4.93; N, 19.57; found C, 75.55; H, 4.90; N, 19.55.

1-(3,5-dimethylphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4f): Color: Pale red solid (69 % yield); M.P: 130-132 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.71 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.52 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.45 (s, 1H, Ar-H), 7.35 - 7.30 (m, 1H, Ar-H), 7.22 (s, 1H, Ar-H), 7.15 (s, 1H, Ar-H), 7.08 - 7.04 (m, 1H, Ar-H), 5.23 (s, 2H, CH₂), 2.37 (s, 6H, 2-CH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.47, 140.24(2C), 139.11, 137.01, 135.14, 128.47, 127.24, 125.37(2C), 124.24, 123.02, 122.07, 121.05, 110.32, 107.65, 42.47, 21.65(2C); ESI-MS(*m/z*): 301 [M+H]. Anal.Cal for C₁₉H₁₆N₄; C, 75.98; H, 5.37; N, 18.65; found C, 75.94; H, 5.39; N, 18.67.

Synthesis and biological activity of fused 1,2,3-triazoles

1-(2,3-dimethylphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4g) : Color: Pale red solid (66 % yield); M.P: 124-126 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.73 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.51 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.44 - 7.40 (m, 2H, Ar-H), 7.35 - 7.27 (m, 3H, Ar-H), 7.22 (s, 1H, Ar-H), 7.09 - 7.05 (m, 1H, Ar-H), 5.23 (s, 2H, CH₂), 2.19 (s, 3H, -CH₃), 1.93 (s, 3H, -CH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.57, 139.38, 138.46, 137.50, 135.43, 131.24, 128.61, 127.46, 125.82, 125.33, 124.80, 123.69, 121.62, 120.56, 110.20, 107.39, 42.41, 19.63, 15.78; ESI-MS(*m/z*): 301 [M+H]. Anal.Cal for C₁₉H₁₆N₄; C, 75.98; H, 5.37; N, 18.65; found C, 75.95; H, 5.39; N, 18.66.

1-(4-chlorophenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4h):Color: Pale yellow solid (76 % yield); M.P: 135-137 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.80 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.71 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.53 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.41 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.34 - 7.30 (m, 1H, Ar-H), 7.19 (s, 1H, Ar-H), 7.09 - 7.05 (m, 1H, Ar-H), 5.24 (s, 2H, CH₂); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.57, 139.38, 136.41, 135.29, 134.27, 128.62(2C), 127.32, 125.29(2C), 124.41, 123.64, 122.08, 121.36, 110.91, 107.55, 42.47; ESI-MS(*m/z*): 307 [M+H]. Anal.Cal for C₁₇H₁₁ClN₄; C, 66.56; H, 3.61; N, 18.26; found C, 66.53; H, 3.63; N, 18.28.

1-(4-bromophenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4i) : Color: White solid (67 % yield); M.P: 143-145 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.73 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.66 - 7.60 (m, 4H, Ar-H), 7.51 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.34 - 7.29 (m, 1H, Ar-H), 7.21 (s, 1H, Ar-H), 7.10-7.04 (m, 1H, Ar-H), 5.24 (s, 2H, CH₂); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.30, 139.51, 135.53, 133.88, 131.23(2C), 127.36, 124.80, 124.11(2C), 123.07, 122.42, 121.22, 120.74, 110.64, 107.56, 42.33; ESI-MS(*m/z*): 351 [M+H] & 353[M+3H]. Anal.Cal for C₁₇H₁₁BrN₄; C, 58.14; H, 3.16; N, 15.95; found C, 58.17; H, 3.14; N, 15.93.

1-(3,5-dichlorophenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4j) : Color: Pale Yellow solid (77 % yield); M.P: 151-153 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.82 (s, 2H, Ar-H), 7.72 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.55 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.42 (s, 1H, Ar-H), 7.33 - 7.27 (m, 1H, Ar-H), 7.23 (s, 1H, Ar-H), 7.11-7.06 (m, 1H, Ar-H), 5.26 (s, 2H, CH₂); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.73, 139.38, 135.44, 134.48, 131.43(2C), 127.42, 124.81, 124.12(2C), 123.33, 122.52, 121.31, 120.22, 110.98, 107.12, 42.22; ESI-MS(*m/z*): 341 [M+H]. Anal.Cal for C₁₇H₁₀Cl₂N₄; C, 59.84; H, 2.95; N, 16.42; found C, 59.81; H, 2.94; N, 16.45.

1-(4-fluorophenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4k) : Color: Pale red solid (73 % yield); M.P: 127-129 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 8.10 (d, *J* = 8.0 Hz, 2H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.37 - 7.33 (m, 1H), 7.21 (s, 1H), 7.11 - 7.06 (m, 1H), 5.27 (s, 2H, CH₂); ESI-MS(*m/z*): 291 [M+H]. Anal.Cal for C₁₇H₁₁FN₄; C, 70.34; H, 3.82; N, 19.30; found C, 70.37; H, 3.80; N, 19.32.

1-(4-(trifluoromethyl)phenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4l) : Color: Pale red solid (67 % yield), ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 8.16 (d, *J* = 8.0 Hz, 2H, Ar-H), 8.05 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.75 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.52 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.38 - 7.33 (m, 1H, Ar-H), 7.22 (s, 1H, Ar-H), 7.11 - 7.05 (m, 1H, Ar-H), 5.26 (s, 2H, CH₂); ESI-MS(*m/z*): 341 [M+H]. Anal.Cal for C₁₈H₁₁F₃N₄; C, 63.53; H, 3.26; N, 16.46; found C, 63.56; H, 3.28; N, 16.42.

1-(4-nitrophenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4m) : Color: Yellow solid (80 % yield); M.P: 150-152 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 8.41 (d, *J* = 8.0 Hz, 2H), 8.21 (d, *J* = 8.0 Hz, 2H), 7.73 (d, *J* = 8.0 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.36 - 7.31 (m, 1H), 7.21 (s, 1H), 7.10 - 7.06 (m, 1H), 5.27 (s, 2H, CH₂); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.77, 147.65, 140.19, 139.14, 135.03, 127.55, 126.17(2C), 124.07, 123.45(2C), 122.95, 122.08, 121.08, 110.72, 107.12, 42.37; ESI-MS(*m/z*): 318 [M+H]. Anal.Cal for C₁₇H₁₁N₅O₂; C, 64.35; H, 3.49; N, 22.07; found C, 64.38; H, 3.47; N, 22.05.

1-(4-ethylphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4n) : Color: White red solid (72 % yield); M.P: 134-136 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.70 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.60 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.50 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.38 - 7.34 (m, 1H, Ar-H), 7.28 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.18 (s, 1H, Ar-H), 7.09-7.05 (m, 1H, Ar-H), 5.23 (s, 2H, CH₂), 2.28 (q, *J* = 4.0 Hz, 2H, -CH₂), 1.68 (t, *J* = 4.0 Hz, 2H, -CH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.73, 141.27, 139.41, 138.10, 135.21, 129.61(2C), 127.83, 127.23(2C), 124.81, 123.66, 122.53, 121.24, 110.53, 107.28, 42.33, 23.20, 13.78; ESI-MS(*m/z*): 301 [M+H]. Anal.Cal for C₁₉H₁₆N₄; C, 75.98; H, 5.37; N, 18.65; found C, 75.94; H, 5.39; N, 18.67.


4-([1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indol-1(4H)-yl)benzotrile (4o): Color: White solid (72 % yield); M.P: 141-143 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.80 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.72 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.50 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.41 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.36 - 7.31 (m, 1H, Ar-H), 7.21 (s, 1H, Ar-H), 7.11 - 7.06 (m, 1H, Ar-H), 5.24 (s, 2H, CH₂); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.48, 139.42, 138.12, 135.38, 127.63, 127.11(2C), 126.10(2C), 124.19, 123.32, 122.42, 121.43, 119.53, 117.54, 110.41, 107.25, 42.22; ESI-MS(*m/z*): 298 [M+H]. Anal.Cal for C₁₈H₁₁N₅; C, 72.72; H, 3.73; N, 23.56; found C, 72.76; H, 3.71; N, 23.54.

1-(4-butylphenyl)-1,4-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (4p) Color: Pale Yellow solid (66 % yield), M.P: 146-148 °C, ¹H-NMR (400 MHz, DMSO-d₆; δ in ppm): 7.72 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.64 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.50 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.35 - 7.30 (m, 1H, Ar-H), 7.24 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.18 (s, 1H, Ar-H), 7.10 - 7.05 (m, 1H, Ar-H), 5.25 (s, 2H, CH₂), 2.68 (t, *J* = 4.0 Hz, 2H, -CH₂), 1.68 - 1.58 (m, 2H, -CH₂), 1.38 - 1.29 (m, 2H, -CH₂), 0.94 (t, *J* = 4.0 Hz, 3H, -CH₃); ¹³C-NMR (100 MHz, DMSO-d₆) δ 161.37, 139.33, 138.14(2C), 135.78, 130.01, 129.14(2C), 128.07, 127.03, 124.22, 123.02, 122.38, 121.44, 110.58, 107.53, 42.47, 34.21, 32.89, 21.65, 13.70; ESI-MS(*m/z*): 329 [M+H]. Anal.Cal for C₂₁H₂₀N₄; C, 76.80; H, 6.14; N, 17.06; found C, 76.84; H, 6.16; N, 17.00.

3. Results and Discussion

3.1. Chemistry

The synthetic procedure utilized to produce the target compounds is depicted in Scheme 1. In dimethylformamide (DMF) with K₂CO₃, a 6-hour reaction of 2-iodo-1*H*-indole (**1**) and propargyl bromide yielded 2-iodo-1-(prop-2-yn-1-yl)-1*H*-indole (**2**). The important stage of the synthesis, 1,3-dipolar cyclo addition followed by C-C bond coupling of the terminal alkyne (**2**) with different aryl azides at 100 °C at MWI, produces good to excellent yields of the corresponding fused [1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole (**4a-4p**).




Scheme 1. Synthesis of fused [1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole scaffolds.

Scheme 2.²¹ depicts the hypothesised mechanism for the synthesis of [1,2,3]triazolo[4',5':3,4]pyrrolo[1,2-a]indole derivatives. The spectral data from the manufactured

Synthesis and biological activity of fused 1,2,3-triazoles

compounds all corresponded completely with the predicted structures, and a sample molecule, **4b**, was also addressed. In the $^1\text{H-NMR}$ signals are at δ 7.78–6.99 (Aromatic-H), 5.25 (s, 2H, CH_2), and 3.84 (s, 3H, $-\text{OCH}_3$), and in the $^{13}\text{C-NMR}$ signals are at 159.79 (C- OCH_3), 56.21 ($-\text{OCH}_3$), and 42.36 ($-\text{NCH}_2$). The $[\text{M}+\text{H}]^+$ peak at m/z 303 in the ESI-mass spectrum confirmed the structure of compound **4b**. The elemental analysis (C, H, and N) data (C, 71.54; H, 4.65; N, 18.51) confirmed the purity of compound **4b**.



Scheme 2. The proposed mechanism for the one-pot cycloaddition–fusion reaction.

3.2. Biological Assay

3.2.1. Antibacterial activity

Using the conventional broth microdilution method, the title compounds (**4a-4p**) were tested for *in vitro* antibacterial activity against gram-positive (G+ve) bacterial strains, with streptomycin serving as a positive control.²² All derived compounds' minimum inhibitory concentrations (MICs) were indicated in $\mu\text{g}/\text{mL}$. The results are shown in Table 1. Table 1 demonstrates that **4h**, **4j**, and **4k** demonstrated more efficient bacterial inhibitory action against *B. subtilis*, with MICs of 3.12, 1.56, and 3.12 $\mu\text{g}/\text{mL}$, respectively, whereas typical streptomycin MICs were 6.26 $\mu\text{g}/\text{mL}$. Compounds **4d**, **4i**, and **4l** showed equipotent antibacterial action against *B. subtilis*, with MIC values of 6.25 $\mu\text{g}/\text{mL}$, whereas the remaining compounds showed moderate to poor activity. Compound **4j** demonstrated more significant activity against *S. aureus*, with a MIC of 1.56 $\mu\text{g}/\text{mL}$, and comparable activity against *S. epidermidis*, having a MIC of 6.25 $\mu\text{g}/\text{mL}$. With MIC values of 6.25 $\mu\text{g}/\text{mL}$, compounds **4h** and **4k** similarly demonstrated equipotent activity against *S. aureus*. The remaining drugs were ineffective against the tested strains (Figure 2).




Figure 2. SAR of target sulfonyl 1,2,3-triazolyl imidazole derivatives**Table 1.** *In vitro* antibacterial activity data of compounds **4a-4p**

Compounds	R	<i>B. subtilis</i>	<i>S. aureus</i>	<i>S. epidermidis</i>
4a	H	25	50	-
4b	4-OMe	12.5	25	50
4c	3,5-diOMe	12.5	12.5	25
4d	3,5-diOMe, 4-Cl	6.25	12.5	6.5
4e	4-Me	50	25	50
4f	3,5-diMe	25	25	25
4g	2,3-diMe	50	-	-
4h	4-Cl	3.12	6.25	12.5
4i	4-Br	6.25	12.5	25
4j	3,5-diCl	1.56	1.56	3.12
4k	4-F	3.12	6.25	12.5
4l	3-CF ₃	6.25	12.5	12.5
4m	4-NO ₂	12.5	25	50
4n	4-C ₂ H ₅	50	-	-
4o	4-CN	25	25	-
4p	4-C ₄ H ₉	-	-	-
Standard	Streptomycin	6.25	6.25	3.12

Note: “-” indicates concentration > 50 µg/mL

3.2.2. Antioxidant Activity

By using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) technique, all of the produced compounds **4a-4p** were tested for free radical scavenging activity in terms of hydrogen donating or radical scavenging ability as reported in the literature.^{23,24} As a blank, control, and reference, methanol (95%), DPPH solution, and standard chemicals (Trolox and ascorbic acid) were utilized. The findings of the analysis of the free radical scavenging ability of the synthesized compounds **4a-4p** revealed that compounds (**4c**, **4d**, and **4j**) have excellent antioxidant activity with IC₅₀ values ranging from 7.26 ± 0.43 to 9.21±1.03 µM (Table 2). These results on comparison with the standard Trolox with IC₅₀ value of 11.05±0.98 µM found to be active by 1.52 fold for **4d**, 1.31 fold for **4c**, and 1.19 fold for **4j**. The compounds **4b**, **4h**, **4k**, and **4l** have shown good scavenging ability with IC₅₀ values 12.12± 0.98 to 13.65± 0.89 µM, respectively. Remaining compounds have shown moderate to weak scavenging ability/capacity with IC₅₀ values ranging from 17.33±1.21 to 31.93±1.93 µM.

Table 2. Antioxidant activity of **4a-4p** by DPPH method

Compound	IC ₅₀ in µM	Compound	IC ₅₀ in µM
4a	23.88± 1.66	4j	9.21±1.03
4b	13.32± 1.12	4k	12.12± 0.98
4c	8.42± 0.67	4l	13.65± 0.89
4d	7.26 ± 0.43	4m	19.42± 1.16
4e	25.35± 1.52	4n	24.81±1.27
4f	18.79 ± 1.43	4o	17.33±1.21
4g	28.62 ± 1.81	4p	31.93±1.93
4h	12.66±1.19	Trolox	11.05±0.98
4i	23.21± 1.13	Ascorbic acid	3.34 ± 0.21

4. Conclusion

Finally, using microwave irradiation and one-pot Cu-catalyzed intramolecular C-H arylation of in situ produced 1,2,3-triazoles, a series of new fused [1,2,3]triazolo [4',5':3,4] pyrrolo[1,2-*a*]indoles (**4a-4p**) were synthesized. *In vitro* antibacterial activity against three different types of gram-positive bacteria was assessed for all of the compounds. The most potent compounds against the bacterial strains tested were **4h**, **4j**, and **4k**. Furthermore, free radical scavenging action in the form of hydrogen donation or radical scavenging ability uses the DPPH method. Compounds **4c**, **4d**, and **4j** were discovered to be more potent antioxidants than normal Trolox. The remaining compounds have moderate to low activity, whereas compounds **4b**, **4h**, **4k**, and **4l** have strong activity. Our next goal is to do time kill tests on human pathogenic organisms utilising **4h**, **4j**, and **4k** chemicals.

Acknowledgements

The authors would like to express their gratitude to the Department of Biotechnology at Kakatiya University in Hanumakonda for providing biological activity data.

Supporting Information

Supporting information accompanies this paper on <http://www.acgpubs.org/journal/organic-communications>

ORCID

Abhilasha Dubba: [0009-0006-4309-3042](https://orcid.org/0009-0006-4309-3042)

Koppula Shiva Kumar: [0000-0002-2586-4257](https://orcid.org/0000-0002-2586-4257)

References

- [1] Cabeen, M. T.; Jacobs-Wagner, C. Bacterial cell shape. *Nat. Rev. Microbiol.* **2005**, *3*, 601–610.
- [2] Gao, C.; Fan, Y. L.; Zhao, F.; Ren, Q. C.; Wu, X.; Chang, L.; Gao, F. quinolone derivatives and their activities against methicillin-resistant *Staphylococcus aureus* (MRSA). *Eur. J. Med. Chem.* **2018**, *157*, 1081–1095.
- [3] Muroi, H.; Nihei, K.; Tsujimoto, K.; Kubo, I. synergistic effects of anacardic acids and methicillin against methicillin resistant *Staphylococcus aureus*. *Bioorg. Med. Chem.* **2004**, *12*, 583–587.
- [4] Sharma, V.; Kumar, P.; Pathak, D. Biological importance of the indole nucleus in recent years: A comprehensive review. *J. Heterocycl. Chem.* **2010**, *47*, 491-502.
- [5] Kumar, K. N.; Neha, K.; Pankaj, A.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. Biomedical importance of indoles. *Molecules* **2013**, *18*, 6620.
- [6] Queiroz, M. R. P.; Abreu, A. S.; Carvalho, M. S. D.; Ferreira, P. M. T.; Nazareth, N.; Nascimento, M. S. Synthesis of new heteroaryl and heteroannulated indoles from dehydrophenylalanines: antitumor evaluation. *Bioorg. Med. Chem.* **2008**, *16*, 5584-5589.
- [7] MacDonough, M. T.; Strecker, T. E.; Hamel, E.; Hall, J. J.; Chaplin, D. J.; Trawick, M. L.; Pinney, K. G. Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3'',4'',5''-trimethoxybenzoyl)-6-methoxyindole (OXi8006). *Bioorg. Med. Chem.* **2013**, *21*, 6831-6843.
- [8] Daly, S.; Hayden, K.; Malik, I.; Porch, N.; Tang, H.; Rogelj, S.; Frolova, L. V.; Lepthien, K.; Kornienko, A.; Magedov, I. V. Unprecedented C-2 arylation of indole with diazonium salts: syntheses of 2,3-disubstituted indoles and their antimicrobial activity. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4720-4723.
- [9] Narsimha, S.; Kumar, N. S.; Swamy, B. K.; Reddy, N. V.; Althaf Hussain, S. K.; Rao, M. S. Indole-2-carboxylic acid derived mono and bis 1,4-disubstituted 1,2,3-triazoles: Synthesis, characterization and evaluation of anticancer, antibacterial, and DNA-cleavage activities. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 1639-1644.
- [10] Dheer, D.; Singh, V.; Shankar, R. Medicinal attributes of 1,2,3-triazoles: Current developments. *Bioorg Chem.* **2017**, *71*, 30–54.

- [11] Bozorov, K.; Zhao, J.; Aisa, H. A. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview. *Bioorg. Med. Chem.* **2019**, *27*, 3511-3531.
- [12] Gondru, R.; Kanugala, S.; Raj, S.; Kumar, C. G.; Pasupuleti, M.; Banothu, J.; Bavantula, R. 1,2,3-triazole-thiazole hybrids: Synthesis, in vitro antimicrobial activity and antibiofilm studies. *Bioorg. Med. Chem. Lett.* **2021**, *33*, 127746.
- [13] Kumar, K. S.; Naikawadi, P. K.; Jatho, R.; Dandela, R. Bimetallic Cu/Pd-catalyzed three-component azide-alkyne cycloaddition/isocyanide insertion: synthesis of fully decorated tricyclic triazoles. *Org. Biomol. Chem.* **2019**, *17*(31), 7320-7324.
- [14] Chandrasekhar, S.; Seenaiyah, M.; Kumar, A.; Reddy, C. R.; Mamidyala, S. K.; Kumar, C. G.; Balasubramanian, S. Intramolecular copper(I)-catalyzed 1,3-dipolar cycloaddition of azido alkynes: Synthesis of triazolo-benzoxazepine derivatives and their biological evaluation. *Tetrahedron Lett.* **2011**, *52*(7), 806-808.
- [15] Reddy, K. R.; Mamatha, R.; Surendra Babu, M. S.; Shiva Kumar, K.; Jayaveera, K. N.; Narayanaswamy, G. Synthesis and antimicrobial activities of some triazole, thiadiazole, and oxadiazole substituted coumarins. *J. Heterocyclic Chem.* **2014**, *51*, 132-137.
- [16] Vennam, D.K.R.; Thatipamula, R.K.; Haridasyam, S.B.; Kumar, K. S. Design, synthesis, and biological evaluation of new 1-aryl-4-(β -D-fructopyranos-3-O-yl)methyl-1H-1,2,3-triazole derivatives. *Chem. Heterocycl. Comp.* **2018**, *54*, 630-637.
- [17] Reddy, T. S.; Rai, S.; Koppula, S. K. Synthesis of indole-tetrazole coupled aromatic amides; In vitro anticancer activity, in vitro tubulin polymerization inhibition assay and in silico studies. *J. Mol. Struct.* **2022**, *1267*, 133556.
- [18] Velidandla, J. M. R.; Koppula, S. K. Organocatalytic [3+ 2] Cycloaddition reaction: synthesis of fully decorated sulfonyl-1, 2, 3-triazolyl pyrimidines as potent anticancer and EGFR inhibitors. *Polycycl. Aromat. Compd.* **2023**. doi:10.1080/10406638.2023.2220864
- [19] Velidandla, J. M. R.; Koppula, S. K. Synthesis of novel imidazolo-[1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine hybrids as in vitro EGFR inhibitors. *Chem. Biol. Lett.*, **2023**, *10*(3), 548.
- [20] Behbehani, H.; Ibrahim, H. M.; Makhseed, S.; Mahmoud, H. Applications of 2-arylhydrazononitriles in synthesis: Preparation of new indole containing 1,2,3-triazole, pyrazole and pyrazolo[1,5-a]pyrimidine derivatives and evaluation of their antimicrobial activities. *Eur. J. Med. Chem.* **2011**, *46*, 1813-1820.
- [21] Ramya, S. E.; Thupurani, M.i K.; Ravinder, M.; Gondru, R.; Sirassu, N. Fused benzo[1,3]thiazine-1,2,3-triazole hybrids: Microwave-assisted one-pot synthesis, in vitro antibacterial, antibiofilm, and in silico ADME studies. *Bioorg. Med. Chem. Lett.* **2021**, *47*, 128201.
- [22] Subramaniam, P.; Nandan, N. Effect of xylitol, sodium fluoride and triclosan containing mouth rinse on *Streptococcus mutans*. *Contemp. Clin. Dent.* **2011**, *2*, 287-290.
- [23] Yayli, N.; Kahriman, N.; Kilic, G.; Serdaroglu, V.; Aliyazicioglu, R.; Sellitepe, H.E.; Karaoglu, S.A.; Yilmaz, G.T. Molecular docking, synthesis and biological evaluation (enzyme inhibition, antimicrobial and antioxidant) of methoxy benzoin/benzil/stilbenoid derivatives. *Org. Commun.* **2022**, *15*(2), 129-147.
- [24] Gul, M. Z.; Ahmad, F.; Kondapi, A. K.; Qureshi, I. A.; Ghazi, I. A. Antioxidant and antiproliferative activities of *Abrus precatorius* leaf extracts - an in vitro study. *BMC Complementary Altern. Med.* **2013**, *13*, 53.